Cytokinetics INC Form 4 insider transactions

Cytokinetics director Robert Arthur Harrington acquired 197 shares of common stock at $63.44 per share on January 15, 2026, as part of an equity compensation plan.

Cytokinetics' EVP, Chief Commercial Officer Andrew Callos, exercised stock options and subsequently sold an equal number of common shares, as per a Rule 10b5-1 plan.

Cytokinetics' EVP, Chief Commercial Officer, Andrew Callos, reported future planned sales of common stock following option exercises under a 10b5-1 plan.

Cytokinetics' EVP, Chief Commercial Officer Andrew Callos, sold 1,809 shares of common stock for $62.44 per share under a Rule 10b5-1 plan.

Cytokinetics CEO Robert I. Blum increased his beneficial ownership through performance share awards, partially offset by tax-related share withholding.

Cytokinetics' EVP of Research & Development, Fady Ibraham Malik, increased his direct beneficial ownership of common stock through performance share awards.

Cytokinetics' Chief Commercial Officer, Andrew Callos, reported the acquisition of performance shares and a tax-related disposition, resulting in a net increase in his direct beneficial ownership.

CYTOKINETICS' EVP and CFO, Sung Lee, reported the acquisition of performance shares and a sale for tax withholding purposes.

Cytokinetics' President and CEO, Robert I. Blum, exercised stock options and adjusted his beneficial ownership of common stock through pre-planned transactions.

Cytokinetics Director Wendell Wierenga exercised stock options and subsequently sold a portion of his common stock holdings under a 10b5-1 plan.

Cytokinetics' EVP of Research & Development, Fady Ibraham Malik, sold 2,200 shares of common stock after exercising incentive stock options.

Cytokinetics EVP and Chief Commercial Officer Andrew Callos exercised stock options and subsequently sold an equal number of common shares under a Rule 10b5-1 plan.

Cytokinetics' EVP and Chief Commercial Officer Andrew Callos exercised stock options and subsequently sold an equal number of common shares under a Rule 10b5-1 plan.

Cytokinetics' EVP and CFO, Sung Lee, sold 1,560 shares of common stock to cover tax obligations related to vested performance stock units.

Cytokinetics' Chief Commercial Officer, Andrew Callos, sold 1,368 shares of common stock to cover tax withholding obligations related to vested performance stock units.

Cytokinetics' EVP of Research & Development, Fady Ibraham Malik, has filed a Form 4 reporting a planned sale of 2,058 shares of common stock on December 3, 2025, to cover tax withholding obligations related to PSUs vested in December 2024.

Cytokinetics CEO Robert I. Blum reported the disposition of 5,930 common shares at $65.02 each to cover tax liabilities, as part of a pre-arranged plan.

Cytokinetics Director John T. Henderson exercised stock options and sold 8,750 shares of common stock under a Rule 10b5-1 plan.

Cytokinetics' EVP of Research & Development, Fady Ibraham Malik, exercised stock options and subsequently sold the acquired common stock in a pre-planned transaction.

A director at Cytokinetics Inc. sold 2,150 shares of common stock for approximately $143,620 under a pre-arranged trading plan.

Cytokinetics Director Edward M. Kaye, MD, exercised stock options and subsequently sold 28,064 shares of common stock for $66.72 per share.

CYTOKINETICS Director B. Lynne Parshall reported the sale of 5,000 shares of common stock for $64.73 per share, executed under a Rule 10b5-1 plan.

Cytokinetics EVP Fady Malik exercised stock options and immediately sold an equal number of shares under a pre-arranged plan.

Cytokinetics Inc. granted 87,297 restricted stock units to its Chief Legal & Admin Officer, Jeffrey Hessekiel, as an initial new hire grant.

A director at Cytokinetics Inc. exercised stock options and subsequently sold a portion of the acquired common stock under a Rule 10b5-1 plan.

Cytokinetics President and CEO Robert I Blum gifted 2,000 shares of common stock to two irrevocable family trusts.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, executed a pre-planned transaction, exercising stock options and selling the acquired common stock.

Cytokinetics CEO Robert I. Blum sold 5,000 shares of common stock for $62.86 per share on October 30, 2025, under a pre-arranged trading plan.

Cytokinetics Director Wendell Wierenga exercised stock options and subsequently sold an equal number of common shares under a pre-arranged trading plan.

Cytokinetics' EVP of Research & Development, Fady Ibraham Malik, executed a pre-planned sale of 2,105 common shares on October 21, 2025, following the exercise of stock options.